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Purpose. Prognostic signiﬁcance of ﬂuorine-18 ﬂuorodeoxyglucose positron emission tomography (18F-FDG-PET) in anal
squamous cell carcinoma (SCC) has been evaluated in several studies; however, the results seem to be controversial and no
consensus exists about its predictive capability. (e current meta-analysis was carried out to comprehensively investigate the
prognostic signiﬁcance of 18F-FDG-PETparameters in patients with anal SCC.Methods. A comprehensive literature search of
PubMed/MEDLINE and Scopus databases was performed to retrieve pertinent articles published until August 5th 2018,
concerning the prognostic signiﬁcance of 18F-FDG-PET in patients with anal SCC. No language restriction was used. Several
prognostic factors were reported for progression-free survival (PFS) and overall survival (OS) including pretreatment
maximum standardized uptake value (SUVmax), metabolic tumor volume (MTV), inguinal nodal uptake, and metabolic
response to therapy. Results. Eleven studies (741 patients) were included. (e pooled hazard ratio (HR) for the probability of
PFS was 5.36 (95% conﬁdence interval (95% CI): 3.12–9.21, p< 0.001) for metabolic response to therapy and 1.98 (95% CI:
1.26–3.12, p � 0.003) for SUVmax. (e pooled HR for the probability of OS was 5.87 (3.02–11.39, p< 0.0001) for metabolic
response to therapy. On the other hand, the study revealed that the pooled HRs of MTV and inguinal nodal uptake for PFS were
1.56 (95% CI: 0.96–2.53, p � 0.072) and 1.79 (95% CI: 1–3.21, p � 0.051), respectively. Conclusions. Our ﬁndings propose that
some 18F-FDG-PET parameters could serve as prognostic indicators in anal SCC, but further larger studies are needed in
this setting.
1. Introduction
Anal carcinomas represent approximately 4% of gastroin-
testinal cancers diagnosed annually, the majority of which
are squamous cell carcinomas (SCCs) [1]. SCC of the anus is
an uncommon malignancy but its incidence has increased
considerably in recent years among women and men
younger than 45 years. Over the past 3 decades, the incidence
of anal SCC has increased by approximately 90% in men and
40% in women [2]. (e rate of metastatic disease, mostly
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observed in the liver and the lungs, is low [3]. HIV and
human papilloma virus- (HPV-) coinfected patients are at
high risk of developing precancerous anal lesions (anal
intraepithelial neoplastic lesions) and anal malignancies.
Progression and persistence of HPV-associated lesions are
known to be enhanced by human immunodeﬁciency virus-
(HIV-) related immunosuppression, which may result in the
reactivation of previously acquired HPV infection and loss
of control of HPV viral replication [4], the phenomenon
which explains the high risk of anal SCC in HIV-infected
patients [2].
(e diagnosis of anal neoplasms is usually made by
physical examination and rectoscopy. In 15–20% of cases,
regional lymph node metastases are present at the time of
diagnosis [4–6]. Endorectal ultrasound (US) and/or pelvic
magnetic resonance imaging (MRI) are required to evaluate
tumor depth and regional spread. Haematogenous spread is
rare at the time of diagnosis, but 40% of deaths during the
course of the disease are due to distant metastases [7]. Anal
carcinomas are categorized according to the TNM staging
system [5]. (e most important prognostic factors for anal
cancer are known to be the tumor size and extent (T) and
nodal involvement (N) [6]. Response to treatment could also
be named as an important prognostic factor for anal cancer
[6]. Recently, positron emission tomography with ﬂuorine-
18 ﬂuorodeoxyglucose (18F-FDG-PET) has become a valu-
able tool for staging, treatment, and surveillance of patients
with various malignancies. Utilization of 18F-FDG-PET for
accurate staging of anal carcinomas is increasing as a result
of several studies performed in this ﬁeld [8]. (ere are few
reports, however, regarding the utility of 18F-FDG-PET as a
prognostic indicator in patients with anal cancer.
Abdominoperineal resection (APR) had been the stan-
dard method of treatment before 1980 for anal SCC, the
mode of therapy which resulted in 5-year recurrence rates of
40–70% and 5-year overall survival (OS) rates of 24–62%.
More recent studies, however, indicated that combined
chemotherapy and radiotherapy could lead to similar OS
rate to surgical treatment [7]. Currently, radiotherapy
combined with 5-ﬂuorouracil (5-FU) and mitomycin or 5-
FU and cisplatin is used as the standard treatment for anal
neoplasms. In the absence of signiﬁcant toxicity, consoli-
dation chemotherapy is continued either for a predeﬁned
time period or until evidence of tumor progression is noted
[9]. Surgical treatment is solely considered in relapsed cases
or cases with no response to chemoradiotherapy [5, 10].
Adoption of such a therapeutic approach for locally ad-
vanced anal SCC has led to a 5-year OS ranging from 61% to
85%. A median OS of only 8–12 months has been reported
for those patients with distant metastatic disease or recurrent
locally advanced disease not amenable to APR [10].
All the data mentioned above indicates the signiﬁcance
of timely determination of disease recurrence and pro-
gression, so as to commence immediate therapeutic ap-
proaches, resulting in a better disease prognostication.
Prognostic performance of 18F-FDG-PET in anal SCC is
unclear: several studies have been published over the years
on this topic with conﬂicting results, not reaching a con-
sensus. In addition, a meta-analysis of published studies
was missing. (e aim of the current investigation is to
systematically review and meta-analyze published data
about the prognostic performance of 18F-FDG-PET in anal
SCC in order to provide evidence-based data in this setting.
2. Methods
2.1. Search Strategy and Study Selection. A comprehensive
computer literature search of PubMed/MEDLINE and
Scopus databases was carried out to retrieve pertinent
published articles concerning the prognostic signiﬁcance
of 18F-FDG-PET in patients with anal SCC. We used a
search algorithm based on a combination of the terms
“(anus OR anal) AND (PET OR positron emission to-
mography).” No language restriction was used. (e search
was performed from inception to August 5th, 2018. (e
bibliographies of eligible studies were also screened to
expand our search.
Studies or subsets in studies were included according to
the following criteria: (1) more than 5 patients with biopsy-
proven anal SCC included; (2) performing at least one 18F-
FDG-PETscan before and/or after treatment; (3) containing
survival data from which the hazard ratio (HR) could be
extractable, providing at least one form of survival data,
namely, progression-free survival (PFS) or overall survival
(OS). Studies investigating the diagnostic role of 18F-FDG-
PET, in vitro studies and animal experiments, case reports,
small case series, review articles, letters, editorials, confer-
ence proceedings, commentaries, and articles containing
insuﬃcient data to calculate the HRs were excluded. (e
studies with the most complete or recent data were included
in case of data overlap in more studies.
Two researchers independently reviewed titles and ab-
stracts of the retrieved articles, applied the above-mentioned
inclusion criteria, rejected ineligible articles, and ﬁnally
evaluated the full-text version of the included articles to
determine their eligibility for inclusion.
2.2. Data Extraction and Quality Assessment. Information
about basic study characteristics (authors, year of publica-
tion, country of origin, study design), patients’ character-
istics (number of patients with anal SCC performing 18F-
FDG-PET, median age, gender, TNM staging of the anal
SCC, and follow-up time), and technical aspects (injected
activity of 18F-FDG, acquisition modality, and time interval
between 18F-FDG administration and scanning) were col-
lected. Furthermore, information about prognostic param-
eters were extracted including maximum standardized
uptake value (SUVmax, calculated as the measure of the
greatest amount of 18F-FDG uptake in a region of interest
divided by body weight), metabolic tumor volume (MTV,
determined from the attenuation-corrected PETdata using a
software), metabolic response to therapy categorized as
complete metabolic response (CMR) and partial metabolic
response (PMR), inguinal nodal uptake (considering as
positive a lymph node with an increased 18F-FDG uptake,
based on the criteria reported by diﬀerent authors) and cut
oﬀ values, as well as the survival data, including PFS and OS
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with HRs with 95% conﬁdence intervals (95% CIs). Only
studies providing such data were ﬁnally recruited in the
meta-analysis.
Two independent reviewers assessed the methodology of
the eligible studies using the Oxford Center for Evidence
Based Medicine guideline to examine the quality of prog-
nostic studies [11]. For each included paper, this tool takes
into account several parameters comprising patient enrol-
ment at a common point in the course of the disease, follow-
up duration, method of veriﬁcation of outcome, blind
outcome assessment of PET ﬁndings, and adjustment for
important prognostic factors, which could aﬀect the ﬁnal
results [11].
2.3. Statistical Analysis. Pooling of HRs and calculation of
their 95% CI was performed using a random eﬀects model
to determine the prognostic signiﬁcance of SUVmax,
MTV, metabolic response to therapy, and inguinal nodal
uptake.
(e I2 statistic was applied to evaluate the heterogeneity
among studies, representing the percentage of total variation
contributed by a between-study variation and ranging from
0% to 100% [12]. (e publication bias was assessed using
funnel plots and Egger’s regression intercept [13]. All sta-
tistical analyses were performed by using Comprehensive
Meta-analysis (version 2, Biostat Inc., USA) software. (e
ﬁnal results were demonstrated as forest plots.
Articles identiﬁed in literature
(n = 429)
Articles evaluated in detail
(n = 35)
Studies included
(n = 11)
Excluded (duplicates or title
and abstract revealed
not appropriate)
(n = 394)
Excluded (conference paper, review
article, letter to editors, editorial, case
report, inadequate data, and low sample
size) (n = 24)
Figure 1: Flow diagram of studies included in the current meta-analysis.
Table 1: Characteristics of selected studies included in the meta-analysis.
First author Year ofpublication
Patient
source
Number of
patients
Median age
(range), years
Gender
(male/female) TNM staging
Study
design
Schwarz et al. [24] 2008 USA 53∗ 52 (30–89) 20/33 6 stage I, 34 stage II, 8 stage IIIA,and 5 stage IIIB P
DeWinton et al. [16] 2009 Australia 61 57 (27–88) 27/34 19 stage I, 16 stage II, 5 stage IIIA,19 stage IIIB, and 2 stage IV P
Mai et al. [23] 2009 Germany 39 59 (37–86) 17/22 9 T1, 21 T2, 5 T3, 4T4, 28 N0, 8 N1,3 N2 P
Kidd et al. [22] 2010 USA 77§ 53 (30–89) 33/44 2 stage 0, 7 stage I, 49 stage II,10 stage IIIA, 9 stage IIIB P
Day et al. [15] 2011 Australia 48 56 (35–87) 22/26 8 stage I, 18 stage II, 6 stage IIIA,14 stage IIIB, and 2 stage IV R
Goldman et al. [19] 2016 USA 148 60 (33–91) 44/104 6 stage I, 64 stage II, 21 stage IIIA,and 58 stage IIIB R
Deantonio et al. [17] 2016 Italy 55Ψ 67 (44–90) 18/38 4 stage I, 25 stage II, 4 stage IIIA,and 22 stage IIIB P
Gauthe´ et al. [18] 2017 France 75 63.8 ± 9.9(40–88) 8/67 5 stage I, 22 stage II, 20 stage IIIA,and 28 stage IIIB R
Cardenas et al. [14] 2017 USA 110 54.5€ 48/62 15 stage I, 47 stage II, 48 stage III R
Houard et al. [21] 2017 France 87 62 (35–89) 19/68 9 T1, 34 T2, 17 T3, 27 T4, 37 N0,50N+ R
Hong et al. [20] 2018 USA 23 60.1€ 5/18 3 T1, 8 T2, 9 T3, 3 T4, 13 N0, 10N+ P∗(e study included 41 cases of squamous cell carcinoma, 8 cases of basaloid carcinoma, 2 cases of adenocarcinoma, 1 case of small cell carcinoma, and 1 case
of adenosquamous carcinoma. §(e study comprised 65 cases of squamous cell carcinoma, 11 cases of basaloid carcinoma, and 1 case of small cell carcinoma.Ψ(e study included 44 cases of squamous cell carcinoma, 3 cases of adenocarcinoma, and 8 cases of cloacogenic carcinoma. €Mean age. P, prospective; R,
retrospective.
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3. Results
3.1. Study Characteristics. (e comprehensive computer
literature search from PubMed/MEDLINE and Scopus
databases revealed a total of 429 records, among which
394 were excluded after titles and abstracts were screened.
(e full-texts of the remaining 35 articles were carefully
evaluated, and eventually 11 articles (741 patients) [14–
24], found to be potentially eligible for inclusion applying
the selection criteria mentioned above, were included in
the current meta-analysis (Figure 1). No additional
studies were retrieved after screening the references of the
selected articles. Basic study characteristics and meth-
odological aspects of the 11 retrieved studies are sum-
marized in Tables 1 and 2. As depicted in Table 2, the
methodological quality of all included studies has been
evaluated according to the Oxford Center for Evidence
Based Medicine guideline to examine the quality of
prognostic studies [11].
In the current review, ﬁve retrospective and six
prospective studies about the prognostic signiﬁcance of
18F-FDG-PET in patients with anal SCC have been
included.
Table 2 demonstrates all the details regarding the PET
prognostic parameters evaluated by each included study.
Among the eligible articles, 5 studies (14, 15, 19, 21, and 24)
evaluated the prognostic signiﬁcance of metabolic response
to treatment and 3 studies (16, 18, and 23) assessed the
prognostic signiﬁcance of inguinal nodal 18F-FDG uptake.
(e prognostic importance of two other parameters,
SUVmax and MTV, has been examined by 5 (14, 17, 18, 20,
and 22) and 2 (18 and 20) investigations, respectively.
3.2. Pooled Prognostic Signiﬁcance. Pooled HRs of MTV,
inguinal nodal 18F-FDG uptake, metabolic response to
therapy, and preoperative SUVmax for PFS were 1.56 (95%
CI: 0.96–2.53, p � 0.07), 1.79 (95% CI: 0.99–3.21, p � 0.05),
5.36 (95% CI: 3.12–9.21, p � 0.01), and 1.98 (95% CI:
1.26–3.12, p< 0.01), respectively (Figure 2). Four of the
eligible studies provided adequate data to perform meta-
analysis of the HRs of metabolic response to therapy for
overall survival (OS) with a pooled HR of 5.87 (3.02–11.39,
p< 0.01) (Figure 3).
3.3.Heterogeneity andPublicationBias. Few pooled analyses
of PET prognostic indices for PFS revealed mild heteroge-
neity (Table 3). Begg’s funnel plot and Egger’s test were used
to examine the publication bias. (e shape of the generated
funnel plots seemed asymmetrical, which could signify the
presence of possible clinically important publication bias.
(en, in order to provide statistical evidence of funnel plot
asymmetry, Egger’s test was carried out. However, no sig-
niﬁcant evidence of publication bias of the present meta-
analysis (Egger’s test p values > 0.1) was detected (Figure 4).
4. Discussion
18F-FDG-PET imaging has been the focus of intensive re-
search, revealing its ever-increasing role in the staging and
management of patients with malignant diseases, and this is
also the case for anal SCC [8]. Most studies on the role of this
imaging modality in anal SCC have focused on its diagnostic
and treatment planning signiﬁcance [25–27]; however, only
a few reports exist, analyzing and quantifying the association
Group by
evaluated factor
Study name Subgroup within study Statistics for each study Hazard ratio and 95% CI
Hazard 
ratio
Lower 
limit
Upper 
limit p value
MTV Gauthé 2017 PFS 2.40 0.90 6.43 0.081
MTV Hong 2018 MTV PFS 1.40 1.04 1.89 0.027
MTV 1.56 0.96 2.53 0.072
PET inguinal uptake De Winton 2009 PFS 1.37 0.78 2.39 0.267
PET inguinal uptake Mai 2009 PFS 2.69 0.20 36.00 0.455
PET inguinal uptake Gauthé 2017 Node PFS 3.09 1.14 8.35 0.026
PET inguinal uptake 1.79 1.00 3.21 0.051
PET metabolic response Day 2011 PFS 4.10 1.48 11.35 0.007
PET metabolic response Schwarz 2008 PFS 7.91 0.79 79.09 0.078
PET metabolic response Goldman 2016 PFS 3.60 1.20 10.80 0.022
PET metabolic response Cardenas 2017 MR PFS 3.28 1.29 8.35 0.013
PET metabolic response Houard 2017 PFS 16.40 5.86 45.87 0.000
PET metabolic response 5.36 3.12 9.21 0.000
SUVmax categorized Kidd 2010 PFS 1.68 0.91 3.09 0.095
SUVmax categorized Deantonio 2016 PFS 1.22 0.55 2.70 0.626
SUVmax categorized Hong 2018 PFS 4.00 0.74 21.54 0.107
SUVmax categorized Cardenas 2017 PFS 3.58 1.14 11.26 0.029
SUVmax categorized Gauthé 2017 SUV PFS 2.61 1.01 6.74 0.048
SUVmax categorized 1.98 1.26 3.12 0.003
0.01 0.1 1 10 100
Figure 2: HRs and 95% conﬁdence intervals of individual studies and pooled data of MTV, inguinal nodal 18F-FDG uptake, PETmetabolic
response to therapy, and categorized SUVmax for PFS. HR, hazard ratio; CI, conﬁdence interval; MTV, metabolic tumor volume; PET,
positron emission tomography; SUV, standardized uptake value; PFS, progression-free survival.
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Study name Subgroup within study Statistics for each study Hazard ratio and 95% CI
Hazard 
ratio
Lower 
limit
Upper 
limit p value
Day 2011 OS OS 6.70 2.09 21.49 0.001
Schwarz 2008 OS OS 5.26 0.08 352.87 0.439
Goldman 2016 OS OS 7.40 2.14 25.53 0.002
Cardenas 2017 MR OS OS 4.38 1.46 13.14 0.008
5.87 3.02 11.39 0.000
0.01 0.1 1 10 100
Figure 3: Hazard ratios and 95% conﬁdence interval of individual studies and pooled data of metabolic response for OS. CI, conﬁdence
interval; OS, overall survival.
Table 3: Pooled data of MTV, inguinal nodal 18F-FDG uptake, metabolic response, and categorized SUVmax for PFS and OS.
HR (95% CI) Overall eﬀect, p value Heterogeneity (d.f.)
PFS
MTV 1.56 (0.96, 2.53) Z � 1.80, p � 0.07 I2 � 5.62% [1]
Inguinal nodal uptake 1.79 (0.99, 3.21) Z � 1.95, p � 0.05 I2 � 3.65% [2]
Metabolic response 5.36 (3.12, 9.21) Z � 6.09, p � 0.00 I2 � 38.31% [4]
Categorized SUVmax 1.98 (1.26, 3.12) Z � 2.95, p � 0.00 I2 � 0% [4]
OS
Metabolic response 5.87 (3.02, 11.39) Z � 5.23, p � 0.00 I2 � 0% [3]
HR, hazard ratio; d.f., degrees of freedom; PFS, progression free survival; MTV, metabolic tumor volume; SUVmax, maximum standardized uptake value; OS,
overall survival.
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Figure 4: Funnel plots of three meta-analyses of the current study, including metabolic response to therapy for PFS (a) and OS (b), and
SUVmax (c).
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between PET metabolic parameters and prognosis of anal
SCC. As described earlier in this paper, some investigations
have indicated the probable roles of certain PET indices,
including the SUVmax on pretreatment 18F-FDG-PET,
MTV, metabolic response as determined by posttherapy
18F-FDG-PET (categorized as complete and partial response
groups), and inguinal nodal 18F-FDG uptake, in yielding
prognostic information on either OS or PFS beyond that of
established prognostic markers in anal SCC [14–24].
(e aforementioned studies on the prognostic value of
18F-FDG-PET in patients with anal SCC have mostly
revealed somehow contradictory results and could not reach
a consensus. (e current meta-analysis aimed to examine
the prognostic signiﬁcance of 18F-FDG-PET in patients with
biopsy-proven anal SCC to provide evidence-based data in
this setting. Data from eleven studies (741 patients) were
gathered and pooled.
18F-FDG-PET may aid in tailoring treatment in patients
with anal SCC based on data in the pretreatment and post-
treatment settings, providing independently useful clinical
information and improving the selection of patients who may
beneﬁt from more aggressive treatment [14, 18, 20, 21].
Our meta-analysis demonstrated that metabolic re-
sponse to therapy and preoperative SUVmax are relevant
prognostic factors in patients with anal SCC; therefore, anal
SCC patients with inadequate metabolic response to therapy
and higher preoperative SUVmax of the anal tumor have a
poorer prognosis and they could beneﬁciate from a more
aggressive treatment (such as adequate inguinal irradiation
or chemotherapy dose escalation or intensiﬁcation) that
cannot be routinely performed due to the expected increased
toxicity [14, 18, 20, 21].
Although the study did not indicate MTV and inguinal
nodal 18F-FDG uptake as statistically signiﬁcant prognostic
factors, the direction of eﬀect was compatible with other
PET metabolic indices. As the number of studies were
limited, statistically nonsigniﬁcant pooled indices for MTV
and inguinal nodal 18F-FDG uptake are most likely due to
low statistical power.
(e current study has some limitations that should be
acknowledged when describing the results. Publication bias is a
major concern in all meta-analyses as studies reporting sig-
niﬁcant positive ﬁndings are more likely to be published than
those reporting negative results. Indeed, it is not unusual for
small-sized early studies to report positive ﬁndings that sub-
sequent larger studies fail to replicate. We cannot exclude that
publication biasmay have inﬂuenced the results of our analysis.
Furthermore, heterogeneity among studies may repre-
sent a potential source of bias in our meta-analysis. (is
heterogeneity is likely to arise through baseline diﬀerences
among the patients in the included studies, diversity in
methodological aspects between diﬀerent studies, and dif-
ferent study quality. (e overall quality of the studies in-
cluded in our analysis was not excellent; this was partly
caused as a result of lack of patients’ recruitment at a
common point of the disease course and the inability of the
authors of eligible studies to carry out blind outcome as-
sessment to the PET ﬁndings. (ese factors make the overall
ﬁndings less reliable.
Another limitation to bementioned is the small number of
patients enrolled in some of the included studies, whichmakes
the results of our meta-analysis to be interpreted with caution.
(e limited number of investigations evaluating the
prognostic signiﬁcance of 18F-FDG-PET parameters can be
considered as a limitation. (erefore, larger multicenter
studies evaluating the prognostic value of several PET pa-
rameters are warranted.
5. Conclusions
Our meta-analysis demonstrates that the metabolic response
to therapy, detected by 18F-FDG-PET, as well as the pre-
operative SUVmax could serve as promising prognostic
markers in patients with biopsy-proven anal SCC. (ese
prognostic markers could indicate which patients may
beneﬁciate from more aggressive treatment. (erefore, 18F-
FDG-PET may aid in tailoring treatment in patients with
anal SCC based on data in the pretreatment and post-
treatment settings, providing independently useful clinical
information, but further large multicenter studies are
needed to strengthen our results.
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